Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 5/20 | 0.57 |
| ▸ | PRKCI | P41743 | 4/20 | 0.55 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.54 |
| ▸ | IKBKB | O14920 | 3/20 | 0.54 |
| ▸ | CHUK | O15111 | 3/20 | 0.54 |
| ▸ | IGF1R | P08069 | 2/20 | 0.54 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.54 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.54 |
| ▸ | JAK2 | O60674 | 1/20 | 0.54 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.54 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.54 |
| ▸ | PAK4 | O96013 | 1/20 | 0.54 |
| ▸ | CSF1R | P07333 | 1/20 | 0.54 |
| ▸ | RET | P07949 | 1/20 | 0.54 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.54 |
| ▸ | PRKACA | P17612 | 1/20 | 0.54 |
| ▸ | FLT1 | P17948 | 1/20 | 0.54 |
| ▸ | LTK | P29376 | 1/20 | 0.54 |
| ▸ | GRK5 | P34947 | 1/20 | 0.54 |
| ▸ | KDR | P35968 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2240671 | 0.80 | AURKB (0.71) | NUDT1PRKCIAURKBIKBKBCHUK | |
| SCHEMBL25324172 | 0.79 | CSNK1D (0.63) | NUDT1AURKBIKBKBCHUKIGF1R | |
| SCHEMBL30509435 | 0.79 | CSNK1D (0.63) | NUDT1AURKBIKBKBCHUKIGF1R | |
| SCHEMBL22620293 | 0.78 | JAK2 (0.42) | NUDT1PRKCIAURKBIKBKBCHUK | |
| SCHEMBL10125564 | 0.76 | NUDT1 (0.64) | NUDT1PRKCIAURKBIKBKBCHUK | |
| SCHEMBL14494761 | 0.76 | NUDT1 (0.64) | NUDT1PRKCIAURKBIKBKBCHUK | |
| SCHEMBL22954350 | 0.76 | JAK1 (0.49) | NUDT1PRKCIAURKBIKBKBCHUK | |
| SCHEMBL29946359 | 0.75 | AURKB (0.57) | NUDT1PRKCIAURKBIKBKBCHUK | |
| SCHEMBL858198 | 0.75 | AURKB (0.57) | NUDT1PRKCIAURKBIKBKBCHUK | |
| SCHEMBL2241248 | 0.75 | TGFBR1 (0.51) | DAPK3MAP4K4PRKACACDK8CLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921376-B2 | Pyrrolopyridines useful as inhibitors of protein kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-12-30 | — | — | US | disclosed |
| CN-101228161-B | Pyrrolopyridines useful as protein kinase inhibitors | VERTEX PHARMA | 2012-10-10 | — | — | CN | disclosed |
| EP-1970445-B1 | METHOD FOR NUCLEIC ACID REPLICATION AND NOVEL ARTIFICIAL BASE PAIRS | RIKEN (JP) | 2012-09-26 | — | — | EP | disclosed |
| EP-1881983-B1 | PYRROLOPYRIDINES USEFUL AS INHIBITORS OF PROTEIN KINASE | VERTEX PHARMA (US) | 2012-01-11 | — | — | EP | disclosed |
| US-8030478-B2 | Method for nucleic acid replication and novel artificial base pairs | RIKEN (JP) | 2011-10-04 | — | — | US | disclosed |
| EP-2354139-A1 | Pyrrolopyridines useful as inhibitors of protein kinase | Vertex Pharmaceuticals Incorporated (US) | 2011-08-10 | — | — | EP | disclosed |
| EP-2354140-A1 | Pyrrolopyridines useful as inhibitors of protein kinase | Vertex Pharmaceuticals Incorporated (US) | 2011-08-10 | — | — | EP | disclosed |
| US-20100036111-A1 | METHOD FOR REPLICATING NUCLEIC ACIDS AND NOVEL UNNATURAL BASE PAIRS | RIKEN (JP) | 2010-02-11 | — | — | US | disclosed |
| EP-1970445-A1 | METHOD FOR NUCLEIC ACID REPLICATION AND NOVEL ARTIFICIAL BASE PAIRS | Riken (JP) | 2008-09-17 | — | — | EP | disclosed |
| CN-101228161-A | Pyrrolopyridines useful as protein kinase inhibitors | VERTEX PHARMA (US) | 2008-07-23 | — | — | CN | disclosed |
| US-20070135466-A1 | Pyrrolopyridines useful as inhibitors of protein kinase | VERTEX PHARMACEUTICALS INCORPORATED | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100036111-A1 | METHOD FOR REPLICATING NUCLEIC ACIDS AND NOVEL UNNATURAL BASE PAIRS | POLM, POLL, POLRMT | NUDT1 21/4885PRKCI 1166/4885AURKB 1337/4885 |
| US-20070135466-A1 | Pyrrolopyridines useful as inhibitors of protein kinase | JAK2, JAK1, JAK3 | NUDT1 2466/4885PRKCI 23/4885AURKB 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.